{
    "title": "115_hr5687",
    "content": "The Act is titled the \"Securing Opioids and Unused Narcotics with Deliberate Disposal and Packaging Act of 2018\" or the \"SOUND Disposal and Packaging Act.\" It introduces safety-enhancing packaging and disposal features for certain drugs. The Secretary may issue an order requiring the holder of a covered application to implement technologies for packaging or disposal of drugs to mitigate abuse or misuse, after consulting with stakeholders. The Secretary may issue an order requiring stakeholders to discuss relevant matters related to drug abuse prevention. Technologies, controls, or measures must be proportionate to the risk of abuse, not overly burdensome on patient access, and reduce the risk of abuse. The order may include specific requirements for packaging or disposal of drugs. The Secretary may issue an order requiring stakeholders to discuss drug abuse prevention measures, including implementing technologies to reduce abuse risk. The order may provide options for implementing required measures and reference packaging or disposal standards from recognized organizations. The Secretary may issue orders related to drug abuse prevention measures, including incorporating internationally recognized standards or FDA guidelines. Orders may apply to specific drug classes, and holders of covered applications must submit proposed changes within 180 days. The Secretary may issue orders for drug abuse prevention measures, holders of covered applications must submit proposed changes within 180 days. The Secretary may issue orders for drug abuse prevention measures, and holders of covered applications must submit proposed changes within 180 days. Changes approved in the supplement must be implemented within 90 calendar days or a longer period approved by the Secretary. The holder of a covered application may propose alternative technologies, controls, or measures for packaging, storage, or disposal if supported by data showing they can mitigate drug abuse risk. The holder of a covered application can propose alternative technologies, controls, or measures for packaging, storage, or disposal to reduce drug abuse risk. Disputes regarding submitted supplements can be appealed using specified dispute resolution procedures. The term 'relevant stakeholders' includes experts in the drug industry, manufacturers, wholesalers, payers, healthcare providers, pharmacists, poison centers, and representatives from various health organizations. The curr_chunk discusses prohibited acts related to drugs approved under a covered application and the required content of an Abbreviated New Drug Application under the Federal Food, Drug, and Cosmetic Act. It involves stakeholders such as healthcare providers, pharmacists, manufacturers, and representatives from health organizations. The curr_chunk discusses the required content of an Abbreviated New Drug Application under the Federal Food, Drug, and Cosmetic Act, including provisions for opioids with specific packaging or disposal measures. The curr_chunk amends the grounds for refusing to approve an Abbreviated New Drug Application under the Federal Food, Drug, and Cosmetic Act to include specific requirements for packaging or disposal measures for opioids. The curr_chunk adds requirements for packaging or disposal measures for opioids in Abbreviated New Drug Applications under the Federal Food, Drug, and Cosmetic Act to mitigate abuse or misuse risks. The curr_chunk specifies that labeling related to packaging or disposal measures for drug products in Abbreviated New Drug Applications should not be seen as changes to permissible labeling or conditions of use, nor should it prevent approval of the drug. The curr_chunk discusses limitations on labeling changes for new drug applications and the type of data the Secretary of Health and Human Services can consider. Additionally, it mentions a GAO report due within 12 months of the Act's enactment. The GAO report due within 12 months of the Act's enactment will contain a description of evidence on the effectiveness of in-home controlled substance disposal products and packaging technologies, ways in which these products are made available to the public, and barriers to their use. The GAO report will include a description of Federal oversight of in-home controlled substance disposal products and packaging technologies, methods recommended for disposal, and the effectiveness of these recommendations in preventing diversion of controlled substances. The curr_chunk describes Federal oversight of controlled substance packaging technologies, including recommended technologies like unit dose packaging. It also discusses the effectiveness of these recommendations in preventing the diversion of legally prescribed controlled substances. The curr_chunk provides recommendations on Federal oversight of in-home controlled substance disposal products and packaging technologies, including evaluating product efficacy. The curr_chunk states that the document was passed by the House of Representatives on June 19, 2018, with Karen L. Haas as the Clerk."
}